All News

9 November 2009

Anti-Malignancy Agent Avastin® Obtained Approval for Additional Indication of Non-Small Cell Lung CancerAntibodies

9 November 2009

GENMAB ANNOUNCES START OF OFATUMUMAB PHASE III HEAD TO HEAD STUDY IN DLBCLAntibodies

9 November 2009

MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 ProgramAntibodies

5 November 2009

Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal CancerAntibodies

4 November 2009

Phase 2 Trial of XOMA 052 to be Initiated in Type 1 Diabetes PatientsAntibodies

3 November 2009

Calmune and Crucell Enter Exclusive Research CollaborationAntibodies

3 November 2009

FibroGen Announces New Research in Anti-CTGF and HIF-PHIAntibodies

3 November 2009

XOMA Signs Antibody Discovery Collaboration With KaketsukenAntibodies

2 November 2009

INNATE PHARMA MOVES FORWARD ANTI-KIR MONOCLONAL ANTIBODY IPH 2101 DEVELOPMENT WITH STUDY EXTENSION IN ACUTE MYELOID LEUKEMIAAntibodies

2 November 2009

GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosusAntibodies

29 October 2009

YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AGAntibodies

29 October 2009

Regeneron’s Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)Antibodies

29 October 2009

Micromet and Sanofi-aventis Sign Global Collaboration and License Agreement for New Solid Tumor BiTE AntibodyAntibodies

28 October 2009

Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal AntibodyAntibodies

28 October 2009

Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory diseaseAntibodies

28 October 2009

ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study with Anti-Factor VIII (TB-402)Antibodies

27 October 2009

GSK and Genmab receive accelerated approval for ArzerraAntibodies

27 October 2009

Vivalis Expands Agreement With Sanofi-Aventis in the Therapeutic Proteins FieldAntibodies

27 October 2009

Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of CancerAntibodies

26 October 2009

Astellas to Terminate the Development of Anti-Human Osteopontin Antibody ASK8007for RAAntibodies

23 October 2009

Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)Antibodies

21 October 2009

Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast CancerAntibodies

21 October 2009

BioWa and NKTT Announce Licensing of BioWa’s POTELLIGENT(R) Technology For Use in Antibody Research and DevelopmentAntibodies

21 October 2009

Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF’s 20th World Diabetes CongressAntibodies

20 October 2009

XOMA Presents First XOMA 052 Cardiovascular Disease Animal Model ResultsAntibodies

20 October 2009

New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroidAntibodies

20 October 2009

GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for BENLYSTA in systemic lupus erythematosusAntibodies

20 October 2009

MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired InfectionsAntibodies

20 October 2009

Crucell Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA ConferenceAntibodies

19 October 2009

ABLYNX PROVIDES AN R&D UPDATE AND ANNOUNCES RECENT TECHNOLOGY ADVANCESAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

PSMA-Targeted Therapy Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

CD40 Agonists & CD40/L Antagonists Pipeline Review

GPC3-Targeted Immunotherapy Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review